Compass Pathways (CMPS) Expected to Post Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.3857) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, analysts expect Compass Pathways to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Compass Pathways Stock Performance

Shares of Compass Pathways stock opened at $11.27 on Tuesday. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -3.58 and a beta of 2.47. The firm’s 50-day moving average is $12.52 and its 200 day moving average is $9.06. Compass Pathways has a 1 year low of $3.92 and a 1 year high of $15.40. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FreeGulliver LLC bought a new stake in shares of Compass Pathways in the fourth quarter worth approximately $310,000. Virtus Investment Advisers LLC lifted its position in Compass Pathways by 56.8% during the fourth quarter. Virtus Investment Advisers LLC now owns 39,471 shares of the company’s stock valued at $272,000 after purchasing an additional 14,297 shares during the period. Royal Bank of Canada lifted its position in Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after purchasing an additional 29,733 shares during the period. Graham Capital Management L.P. boosted its holdings in Compass Pathways by 147.2% in the fourth quarter. Graham Capital Management L.P. now owns 36,144 shares of the company’s stock worth $249,000 after purchasing an additional 21,520 shares during the last quarter. Finally, HighTower Advisors LLC boosted its holdings in Compass Pathways by 172.8% in the fourth quarter. HighTower Advisors LLC now owns 31,491 shares of the company’s stock worth $217,000 after purchasing an additional 19,949 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CMPS. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a report on Tuesday, July 7th. Wells Fargo & Company initiated coverage on shares of Compass Pathways in a report on Monday. They set an “equal weight” rating and a $13.00 price target on the stock. Compass Point set a $25.00 price target on shares of Compass Pathways in a research report on Tuesday, July 7th. Raymond James Financial reissued a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Finally, Canaccord Genuity Group boosted their price objective on shares of Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.